Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey

Basit Öğe Kaydı
dc.contributor.authorKucukdiler, Ayse Hilal Eroglu
dc.contributor.authorYavasoglu, Irfan
dc.contributor.authorSelim, Cem
dc.contributor.authorMutlu, Cansu Atmaca
dc.contributor.authorKarakus, Abdullah
dc.contributor.authorKoyuncu, Mahmut Bakir
dc.contributor.authorBilgir, Oktay
dc.date.accessioned2024-04-24T16:15:25Z
dc.date.available2024-04-24T16:15:25Z
dc.date.issued2021
dc.departmentDicle Üniversitesien_US
dc.description.abstractWe retrospectively evaluated the use of gemtuzumab ozogamicin (GO) in relapsed refractory (R/R) acute myeloid leukemia (AML) patients. Twenty-one CD33 positive R/R AML patients who received GO as a single agent in 4 hematology centers were included in this study. The median age was 59, and the median ECOG performance score was 2. According to cytogenetic analysis, 1 patient had favorable risk, 12 patients with in-termediate, and 8 patients with adverse risk. The overall response rate was 52.3%. Partial response was achieved in 3 of 8 patients with adverse risk. 33.3% of patients developed grade 3 anemia. Grade 4 neutropenia and thrombocytopenia were observed in 80% of the patients. One of the patients died due to sinusoidal obstruction syndrome / veno-occlusive disease (SOS / VOD) due to GO side effects. GO may be considered as a good option for salvage therapy in R/R AML patients.en_US
dc.identifier.doi10.1016/j.lrr.2021.100280
dc.identifier.issn2213-0489
dc.identifier.pmid34849337
dc.identifier.scopus2-s2.0-85119300086
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1016/j.lrr.2021.100280
dc.identifier.urihttps://hdl.handle.net/11468/15794
dc.identifier.volume16en_US
dc.identifier.wosWOS:001051152700005
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherElsevier Advanced Technologyen_US
dc.relation.ispartofLeukemia Research Reports
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGemtuzumab Ozogamicinen_US
dc.subjectAcute Myeloid Leukemiaen_US
dc.subjectSalvage Treatmenten_US
dc.titleUse of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkeyen_US
dc.titleUse of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu